FDA Cardio-Renal Head Throckmorton Named CDER Acting Deputy
This article was originally published in The Tan Sheet
Executive Summary
FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is moving up to the position of acting deputy director of CDER, effective May 3
You may also be interested in...
CDER appointment
Douglas Throckmorton, MD, is appointed to the permanent post of CDER Deputy Director, FDA's Center for Drug Evaluation & Research announces Sept. 22. Throckmorton has been acting in the position since May 2004 (1"The Tan Sheet" April 19, 2004, p. 9). Throckmorton started at FDA in 1997 as a medical officer in the Division of Cardiovascular & Renal Drug Products, became deputy director of the division in 2000 and was appointed division director in 2002. "Doug's medical, regulatory and leadership skills make him an outstanding addition to CDER's senior management team and I am honored that he has agreed to continue as my deputy," CDER Director Stephen Galson states...
CDER appointment
Douglas Throckmorton, MD, is appointed to the permanent post of CDER Deputy Director, FDA's Center for Drug Evaluation & Research announces Sept. 22. Throckmorton has been acting in the position since May 2004 (1"The Tan Sheet" April 19, 2004, p. 9). Throckmorton started at FDA in 1997 as a medical officer in the Division of Cardiovascular & Renal Drug Products, became deputy director of the division in 2000 and was appointed division director in 2002. "Doug's medical, regulatory and leadership skills make him an outstanding addition to CDER's senior management team and I am honored that he has agreed to continue as my deputy," CDER Director Stephen Galson states...
CDER appointment
Douglas Throckmorton, MD, is appointed to the permanent post of CDER Deputy Director, FDA's Center for Drug Evaluation & Research announces Sept. 22. Throckmorton has been acting in the position since May 2004 (1"The Tan Sheet" April 19, 2004, p. 9). Throckmorton started at FDA in 1997 as a medical officer in the Division of Cardiovascular & Renal Drug Products, became deputy director of the division in 2000 and was appointed division director in 2002. "Doug's medical, regulatory and leadership skills make him an outstanding addition to CDER's senior management team and I am honored that he has agreed to continue as my deputy," CDER Director Stephen Galson states...